Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

3.540 -0.160 (-4.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 453,836
Open 3.680
Bid (Size) 3.460 (2)
Ask (Size) 3.550 (7)
Prev. Close 3.700
Today's Range 3.465 - 3.730
52wk Range 3.465 - 26.80
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into C4 Therapeutics's Return On Capital Employed
 
Via Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga

Performance

YTD
-44.51%
-44.51%
1 Month
-33.58%
-33.58%
3 Month
-34.69%
-34.69%
6 Month
-58.69%
-58.69%
1 Year
-85.54%
-85.54%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview
Via Benzinga
C4 Therapeutics: Q3 Earnings Insights
Via Benzinga
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via Globe NewsWire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
From C4 Therapeutics, Inc.
Via Globe NewsWire
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
Via Benzinga
Recap: C4 Therapeutics Q2 Earnings
Via Benzinga
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
From C4 Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via Globe NewsWire
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via Globe NewsWire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Via Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via Globe NewsWire
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
From C4 Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Via Benzinga
C4 Therapeutics's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.